Purdue agrees $270 million Oklahoma opioid settlement

27 March 2019

Privately-held Purdue Pharma has agreed to pay for the establishment of the USA’s leading addiction research center in a settlement with the state of Oklahoma over the opioid crisis that its drug OxyContin (oxycodone) contributed to.

The facility will be called the National Center for Addiction Studies and Treatment. Its mission will be to improve the lives of people in Oklahoma and across the country that are affected by pain and substance use disorders through programs focused on research, education, treatment, and public policy initiatives, and it will be housed at Oklahoma State University (OSU) in Tulsa.

Craig Landau, president and chief executive, Purdue Pharma, said: “Purdue is very pleased to have reached an agreement with Oklahoma that will help those who are battling addiction now and in the future.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK